Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant – IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting … Read More →
CADTH Pharmaceutical Reviews Update – July 2019
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency … Read More →
pCPA Closing More Negotiations Without Agreements
pan-Canadian Pharmaceutical Alliance (pCPA): July 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of July 31, 2019. Highlights since the last update include: 5 products completed CADTH review, for a total of 12 files under consideration; 7 products initiated pCPA negotiations, for a total of 47 active negotiations; 6 negotiations completed for a total … Read More →
Number of Active Negotiations (49) at Highest Level Since November 2018
pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include: 6 products completed CADTH review, for a total of 15 files under consideration; 9 products initiated pCPA negotiations, for a total of 49 active negotiations; 4 negotiations completed for a total … Read More →
The pCPA Initiates Negotiations for a Second “Group” of Oncology Biosimilars
pan-Canadian Pharmaceutical Alliance (pCPA): May 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of May 31, 2019. Highlights since the last update include: 2 negotiations completed for a total of 253 completed negotiations; 2 negotiations closed, for a total of 37 closed negotiations; 1 file closed without negotiations, for a total of 65 declined … Read More →
April 2019 pCPA Update: The pCPA has completed over 250 negotiations
pan-Canadian Pharmaceutical Alliance (pCPA): April 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of April 30, 2019. Highlights since the last update include: 4 negotiations completed for a total of 251 completed negotiations No negotiations closed, for a total of 35 closed negotiations 1 file closed without negotiations, for a total of 64 declined … Read More →
March 2019 pCPA Update: Two negotiations initiated prior to completion of CADTH process
pan-Canadian Pharmaceutical Alliance (pCPA): March 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of March 31, 2019. Highlights since the last update include: 5 negotiations completed for a total of 247 completed negotiations 2 negotiations closed, for a total of 35 closed negotiations No new files closed without negotiations, for a total of 63 … Read More →
pCPA Trends and Insights – Two Biosimilars Initiated Negotiations and Two Multi-Indication Negotiations were Completed
pan-Canadian Pharmaceutical Alliance (pCPA): February 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of February 28, 2019. The key highlights since the last update are: 8 negotiations were completed for a total of 242 completed negotiations No negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations … Read More →
MORSE Consulting Releases its 2018 pCPA Year in Review Infographic
MORSE Consulting is pleased to release its 2018 pCPA Year in Review infographic. The purpose of this resource is to help market access professionals provide a top-line pCPA performance summary to both internal and external stakeholders. This infographic compares the negotiation activities of the pCPA in 2018 to 2017 as it relates to: completed negotiations by source (CDR, pCODR, pCPA initiated); a breakdown of … Read More →
Summary of PMPRB Webinar on Meds Entry Watch, 2017
MORSE Consulting has prepared a summary of the key highlights from the Patented Medicines Prices Review Board’s (PMPRB) recent webinar on the release of their Meds Entry Watch 2017 report (third edition). Date: February 20th 2019 Time: 1pm-2pm Presented by: Elena Lungu (Manager NPDUIS, PMPRB), Jared Berger (Policy Analyst, Policy and Economic Analysis Branch, PMPRB) Objective: To present the Meds Entry Watch, 2017 report … Read More →
A Healthcare-focused Analysis of British Columbia’s 2019 Budget
MORSE Consulting is pleased to release a new report by Stephen Filbey of WestPAR Consulting, one of its strategic partners, entitled A Pharma industry Perspective/Opinion on British Columbia’s 2019 Budget. The NDP Government of BC, under the first non-majority legislature since 1952, has just released its second budget. With a strong economy, balanced operating budget, and an estimated $340 million in surplus over the … Read More →
pCPA Negotiation Status Update January 2019 – Two Oncology Negotiations Closed without LOI
pan-Canadian Pharmaceutical Alliance (pCPA): January 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of January 31, 2019. The key highlights since the last update are: 3 negotiations were completed for a total of 234 completed negotiations 3 negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations … Read More →
Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health … Read More →
pCPA Process Timelines Highlights – A Year-in-Review Primer
pan-Canadian Pharmaceutical Alliance (pCPA): December 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) issued the status of brand negotiations as of December 31, 2018. The key highlights since the November update are: 5 products received a final HTA recommendation, for a total of 13 files under consideration 2 products initiated pCPA negotiations, for a total of 46 active negotiations 7 negotiations … Read More →
pCPA Complete its Most Active Month by Adjudicating 15 Files in November
pan-Canadian Pharmaceutical Alliance (pCPA): November 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of November 30, 2018. The key highlights since the October update are: 7 new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; 9 negotiations were completed for a total of 225 completed negotiations; and 2 … Read More →
MORSE Consulting Inc. | Deciphering pharmaceutical market access signals to create reimbursement success.
© 2019 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Market Access Signals - Latest in Pharmaceutical Reimbursement
